Mechanisms of Weight Loss With SGLT2 Inhibition

Completed · Phase 4 · Has a placebo group

Conditions studied: Type 2 Diabetes, Overweight, Obesity

In brief

The purpose of this study is to investigate the effect of canagliflozin, a medication approved by the FDA for the treatment of type 2 diabetes, on body weight and metabolism in people with type 2 diabetes who are overweight or obese. Canagliflozin lowers glucose levels in the blood by making the kidneys excrete, rather than absorb, glucose. Canagliflozin is also often associated with weight loss. The study population will generally be type 2 diabetics, ages 18-75 years old, who are overweight or obese.

Key facts

Study ID

NCT02360774

Run by

Beth Israel Deaconess Medical Center

People needed

30

Starts

2015-02-01

Expected to finish

2018-08-01

Last updated by the study team

2018-08-03

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Type 2 diabetes
• BMI 25-45 kg/m2
• Hemoglobin A1C > 6.5% but < 9%
• Normal renal function (GFR > 60)
• Age 18-75

You may not qualify if…

• Type 1 diabetes
• History of recurrent UTI or mycotic genital infections
• Treatment with insulin or a GLP1 agent
• Pregnant or breastfeeding

Where it is running

• Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.